• B. Eriksson
  • K. Öberg


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Clemmesen J (1965) Statistical studies in the aetiology of malignant neoplasma. II Munksgaard, Copenhagen. Danish Cancer Registry under National Anti-Cancer LeagueGoogle Scholar
  2. 2.
    Bradley L III (1975) Primary and adjunctive therapy in carcinoma of the adrenal cortex. Surg Gynecol Obstet 141:507PubMedGoogle Scholar
  3. 3.
    Luton JP, Cerdas S, Billaud L et al. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy 322 (17): 195–1201Google Scholar
  4. 4.
    Yano T, Linehan M, Anglard T et al. (1989) Genetic changes in human adrenocortical carcinomas. J N C I 81 (7) :518–523Google Scholar
  5. 5.
    Cibas E, Medeiros J, Weinberg D et al. (1990) Cellular DNA Profiles of Benign and Malignant Adrenocortical Tumors 14 (10): 948–955Google Scholar
  6. 6.
    Macfarlane D (1958) Cancer of the adrenal cortex. The natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23:155–185PubMedGoogle Scholar
  7. 7.
    Grondai S, Eriksson B, Hagenäs L et al. (1990) Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endorinol (Copenh) 122:656–663Google Scholar
  8. 8.
    Bodie B, Novick A, Pontes E et al. (1989) The Cleveland Clinic experience with adrenal cortical carcinoma. J of Urol 141:257–260Google Scholar
  9. 9.
    Thompson NW (1983) Adrenocortical carcinomas. In: Thompson NW, Vinik AI, (eds) Endocrine Surgery Update, Grane and Stratton, New YorkGoogle Scholar
  10. 10.
    Schteingardt DE, Motazedi A, Noonan RA, Thompson NW (1982) Treatment of adrenal carcinomas. Arch Surg 117:1142–1146CrossRefGoogle Scholar
  11. 11.
    Lubitz JA, Freeman L, Okun R. Mitotane ause in inoperable adrenal cortical carcinoma. JAMA 223:1109–1112Google Scholar
  12. 12.
    Eriksson B, Öberg K, Curstedt T et al. (1987) Treatment of hormone-producing adrenocortical cancer with o.p’DDD and streptozocin 59 (8): 1398–1403Google Scholar
  13. 13.
    Flack MR, Pyle RG, Mullen NM et al. (1993) Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76:1019–1024PubMedCrossRefGoogle Scholar
  14. 14.
    Stein LA, La Rocca R, Thomas R et al. (1989) Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncology 7 (4): 499–508Google Scholar
  15. 15.
    van Slooten H, Moolenar AJ, van Seters AP, Smeenk F (1984) The treatment of adrenocortical carcinoma with o.p’DDD: prognostic simplications of serum level monitoring Eur J Cancer Clin Oncol 20 (11):47–53PubMedCrossRefGoogle Scholar
  16. 16.
    Tattersall MHN, Lander H, Bain B et al. (1980) Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1:419–421PubMedGoogle Scholar
  17. 17.
    Haq M, Legha S, Samaan N et al. (1980) Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 64:909–913PubMedGoogle Scholar
  18. 18.
    van Slooten H, van Oosterom AT (1983) CAP (Cyclophosphamide, Doxorubicin and Cisplatin) Regimen in Adrenal Cortical Carcinoma. Cancer Treat Rep 67 (4):377–379PubMedGoogle Scholar
  19. 19.
    Johnson D, Greco A (1986) Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16) Cancer 58:2198–2202PubMedCrossRefGoogle Scholar
  20. 20.
    Crocket P, Clark ACL (1989) Combination chemotherapy for adrenal carcinoma: response in a 51/2-year-old male. Medical and Pediatric Oncology 17:62–65CrossRefGoogle Scholar
  21. 21.
    Schlumberger M, Brugierers L, Gicquel C et al. (1991) 5-Fluorouracil, doxorubine and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67:2997–3000PubMedCrossRefGoogle Scholar
  22. 22.
    Page DL, DeLellis RA, Hough AJ (1986) Tumors of the adrenal. In: Atlas of Tumor Pathology, Washington DC, AFIPGoogle Scholar
  23. 23.
    Manager WM, Gifford RW Jr, Hoffman BB (1985) Pheochromocytoma a clinical and experimental overview. Curr Probl Cancer 9:1Google Scholar
  24. 24.
    Irvin GL, Fishman LM, Sher JA (1983) Familial pheochromocytoma. Surgery 94:938PubMedGoogle Scholar
  25. 25.
    Cryer PE (1985) Pheochromocytoma. Clin Endocrinol Metab 14:203PubMedCrossRefGoogle Scholar
  26. 26.
    Lewis PD (1971) A cytophotometric study of benign and malignant pheochromo-cytomas. Virchows Arch 9:371Google Scholar
  27. 27.
    Medeiros LJ, Wolf BC, Balogh K et al. (1985) Adreanl pheochromocytoma a clinicopathologic review of 60 cases. Hum Pathol 16:580PubMedCrossRefGoogle Scholar
  28. 28.
    van Heerden JA, Sheps SG, Hamberger B et al. (1982) Pheochromocytoma: current status and changing trends. Surgery 91:367PubMedGoogle Scholar
  29. 29.
    Bravo EL, Gifford RW Jr (1984) Pheochromocytoma diagnosis, localisation and management. N Engl J Med 311:1298–1303PubMedCrossRefGoogle Scholar
  30. 30.
    Modlin IM, Farndon JR, Shepherd A et al. (1979) Pheochromocytoma in 72 patients: clinial and diagnostic features, treatment and long term results. Br J Surg 66:456–465PubMedCrossRefGoogle Scholar
  31. 31.
    Sheedy PE II, Hattery RR, Stephens DH et al. (1983) Computed tomography of the adrenal gland. In: Hagga JR, Alfidi FJ (eds) Computed Tomography of the whole Body, Vol 2 St Louis C.V. Mosby 681–697Google Scholar
  32. 32.
    Reinig JW, Doppman JL (1986) Magnetic resonance imaging of the adrenal. Radiologe 26:186PubMedGoogle Scholar
  33. 33.
    Shapiro B, Copp JE, Sisson JC et al. (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576PubMedGoogle Scholar
  34. 34.
    Ross EJ, Richard BNC, Kaufmann L et al. (1969) Preoperative and operative management of patients with pheochromocytoma: Anesth Analg Reanimatol 59:154–162Google Scholar
  35. 35.
    Shapiro B, Sisson JC, Wieland DM (1991) Radiopharmaceutical therapy of malignant pheochromocytoma with I131 metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 35:269–276PubMedGoogle Scholar
  36. 36.
    Lumbroso J, Schlumberger M, Tenenbaum F et al. (1991) I131-metaiodoben-zylguanidine therapy in 10 patients with malignant pheochromocytoma. J Nucl Biol Med 35:288–291PubMedGoogle Scholar
  37. 37.
    Krempf F, Lumbroso J, Mornex R et al. (1991) Treatment of malignant pheochromocytoma with I131 metaidobenzylguanidine: a French multicenter study. J Nucl Biol Med 35:284–287PubMedGoogle Scholar
  38. 38.
    Troncone L, Ruffini V, Daidone MS et al. (1991) I131-metaidobenzylguanidine treatment of malignant pheochromocytoma: experience of the Roma groupGoogle Scholar
  39. 39.
    Keiser H, Goldstein DS, Wade JL et al. (1985) Treatment of malignant pheochromocytoma with combination chemotherapy: Hypertension 1–18–24CrossRefGoogle Scholar
  40. 40.
    Averbuch SD, Steakley CR, Young RC et al. (1988) Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, Vincristine and Dacarbazine. Ann Int Med 109:267–273PubMedCrossRefGoogle Scholar
  41. 41.
    Feldman JM (1983) Treatment of metastatic pheochromocytoma with strepto-zocin. Arch Int Med 143:1799–1800CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • B. Eriksson
  • K. Öberg

There are no affiliations available

Personalised recommendations